Copyright
©The Author(s) 2022.
World J Clin Cases. Sep 26, 2022; 10(27): 9556-9572
Published online Sep 26, 2022. doi: 10.12998/wjcc.v10.i27.9556
Published online Sep 26, 2022. doi: 10.12998/wjcc.v10.i27.9556
Table 4 Measures to prevent ventricular arrhythmias[58]
| Measures to prevent ventricular arrhythmias |
| Stop QT prolonging drugs in patients with baseline QTc > 500 ms or with known LQTS |
| Stop QT prolonging drugs when QTc increases to > 500 ms or if QTc is prolonged by > 60 ms compared to baseline measurement |
| Control effectively fever in Brugada patients |
| Avoid the use of chloroquine/hydroxychloroquine, macrolides, fluoroquinolones, and protease inhibitors in patients with known risk factors such as prolonged QTc and electrolyte abnormalities (hypokalemia and hypomagnesemia) |
| Avoid concomitant use of QT prolonging antiarrhythmic drugs, including class IA and class III agents |
| Avoid hypokalaemia and hypomagnesemia |
| Monitor QT via ECG or kardia mobile application |
- Citation: Vidal-Perez R, Brandão M, Pazdernik M, Kresoja KP, Carpenito M, Maeda S, Casado-Arroyo R, Muscoli S, Pöss J, Fontes-Carvalho R, Vazquez-Rodriguez JM. Cardiovascular disease and COVID-19, a deadly combination: A review about direct and indirect impact of a pandemic. World J Clin Cases 2022; 10(27): 9556-9572
- URL: https://www.wjgnet.com/2307-8960/full/v10/i27/9556.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i27.9556